Urovant Sciences cashes in $75m in licence deal from Pierre Fabre

Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales milestones as well as royalties based on sales from Pierre Fabre for the right to commercialise vibegron in EEA countries, Switzerland and the UK plus an option to commercialse it in French-speaking northern African countries, while Urovant will retain full commercialisation rights in the US bull market with 30-40 million patienzts and other markets.

Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Urovant’s beta-3 agonist got FDA approval as symptomatic treatment of OAB in December 2020. The small molecule drug is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company’s second product candidate, URO-902 (formerly hMaxi-K), is a novel gene therapy licenced from Ion Channel Innovations and being developed for patients with OAB symptoms who have failed oral pharmacologic therapy.